If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
ARYA Sciences Acquisition III (ARYA)
Upcoming IPO
Vistas Media Acquisition (VMACU)
Hitek Global (HKIT)
Presidio Property Trust (SQFT)
PainReform (PRFX)
PaxMedica (PXMD)
Duck Creek Technologies, Inc. (DCT)
Priced IPO
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
Rackspace Technology, Inc. (RXT)
BigCommerce Holdings, Inc (BIGC)
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
More companies

Royalty Pharma plc (RPRX)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since their founding in 1996, they have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. They have assembled a portfolio of royalties which entitles them to payments based directly on the top-line sales of many of the industry’s leading therapies, including Imbruvica, Januvia, Kalydeco, Trikafta, Truvada, Tysabri and Xtandi. They fund innovation in the biopharmaceutical industry both directly and indirectly—directly when they partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when they acquire existing royalties from the original innovators. They believe that their significant scale, flexible business model and extensive expertise uniquely position them to take advantage of the increasing innovation in the biopharmaceutical industry. They seek to create favorable outcomes for all parties and play an important role in providing capital to the biopharmaceutical ecosystem that supports innovation and positively impacts human health.
Pablo Legorreta Terrance Coyne
Employees Founded
35 1996


Address: 110 East 59th Street, New York, NY 10022, US

Telephone: (212) 883-0200

Web page:

IPO information

Expected Date 6/16/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $15777.5
Revenues (MM) $1880.25
Net Income (Loss) (MM) $2052.3


What do you think will happen with the RPRX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 70
Shares Revised (MM) 77.7
Expected offer amount (MM) $2175.1
Realized offer amount(MM) $2175.6
JP Morgan/ Morgan Stanley/ BofA Securities/ Goldman Sachs/ Citigroup/ UBS/ Evercore ISI/ Cowen/ SunTrust Robinson Humphrey
BBVA/ DNB Markets/ Scotiabank/ TD Securities

Sector: Healthcare

Tweets about $RPRX

Tweets volume:

RT volume:


Google Trends Stats